Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration ; volume:14 ; number:1 ; day:17 ; month:10 ; year:2024 ; pages:1-7 ; date:12.2024
Scientific reports ; 14, Heft 1 (17.10.2024), 1-7, 12.2024
- Creator
-
Lee, Bokyeong
Kim, Minjee
Kim, Eun Ran
Hong, Sung Noh
Chang, Dong Kyung
Kim, Young-Ho
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-75693-7
- URN
-
urn:nbn:de:101:1-2501062117462.121073623662
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Bokyeong
- Kim, Minjee
- Kim, Eun Ran
- Hong, Sung Noh
- Chang, Dong Kyung
- Kim, Young-Ho
- SpringerLink (Online service)
Other Objects (12)
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
Risk factors for inadequate bowel preparation before colonoscopy: a retrospective cohort study
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
Risk factors for inadequate bowel preparation before colonoscopy: a retrospective cohort study
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
Risk factors for inadequate bowel preparation before colonoscopy: a retrospective cohort study
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials